Table 3. The effects of exposure to chronic, unpredictable stress (CUS) and/or concurrent treatment with the antidepressant imipramine (IMI; 10 mg/kg) on the tissue content (nmol/g tissue) of the endocannabinoid 2-arachidonylglycerol (2-AG).

Exposure of male rats to 21 days of CUS resulted in a significant increase in 2-AG content within the hypothalamus and the midbrain, neither of which was reversed by concurrent IMI treatment. Significant differences from non-stressed (CON), vehicle (VEH) treated animals (p < 0.05) denoted by *. For all treatment conditions, n = 7–8. Data are presented as mean nmol/g tissue +/− SEM.

	CON/VEH	CUS/IMI	CON/VEH	CUS/IMI
Prefrontal Cortex	4.35 +/− 0.29	5.16 +/− 0.14	5.60 +/− 0.45	5.63 +/− 0.52
CUS × IMI F (1, 27) = 0.82, p > 0.05; CUS F (1, 27) = 0.93, p > 0.05; IMI F (1, 27) = 3.93, p > 0.05
Hippocampus	6.37 +/− 0.64	6.11 +/− 0.45	6.82 +/− 0.69	7.04 +/− 0.59
CUS × IMI F (1, 26) = 0.08, p > 0.05; CUS F (1, 26) = 0.00, p > 0.05; IMI F (1, 26) = 1.28, p > 0.05
Hypothalamus	8.25 +/− 0.96	12.92 +/− 0.60*	8.38 +/− 0.76	13.56 +/− 0.98*
CUS × IMI F (1, 25) = 0.10, p > 0.05; CUS F (1, 25) = 35.76, p < 0.001; IMI F (1, 25) = 0.22, p > 0.05
Ventral Striatum	5.81 +/− 0.77	6.26 +/− 0.45	4.71 +/− 0.27	5.68 +/− 0.26
CUS × IMI F (1, 27) = 0.32, p > 0.05; CUS F (1, 27) = 2.41, p > 0.05; IMI F (1, 27) = 3.33, p > 0.05
Amygdala	9.57 +/− 0.68	8.84 +/− 1.04	7.91 +/− 0.94	10.60 +/− 1.08
CUS × IMI F (1, 25) = 3.00, p > 0.05; CUS F (1, 25) = 0.98, p > 0.05; IMI F (1, 25) = 0.00, p >0.05
Midbrain	4.00 +/− 0.31	5.71 +/− 0.44*	5.02 +/− 0.40	5.73 +/− 0.19*
CUS × IMI F (1, 27) = 2.03, p > 0.05; CUS F (1, 27) = 11.89, p < 0.005; IMI F (1, 27) = 2.20, p > 0.05